Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment

Por Westhovens, R, van Riel, P, Sibilia, J, Vratsanos, G, Nuamah, I, Becker, JC
Publicado em 2004

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

Por Genant, H K, Peterfy, C G, Westhovens, R, Becker, J-C, Aranda, R, Vratsanos, G, Teng, J, Kremer, J M
Publicado em 2008

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (th...

Por Emery, P, Durez, P, Dougados, M, Legerton, C W, Becker, J-C, Vratsanos, G, Genant, H K, Peterfy, C, Mitra, P, Overfield, S, Qi, K, Westhovens, R
Publicado em 2009

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging p...

Por Buch, M H, Boyle, D L, Rosengren, S, Saleem, B, Reece, R J, Rhodes, L A, Radjenovic, A, English, A, Tang, H, Vratsanos, G, O’Connor, P, Firestein, G S, Emery, P
Publicado em 2009